Factors associated with fatal cases of acute respiratory infection (ARI) among hospitalized patients in Guatemala

Sara Tomczyk¹, John P. McCracken²*, Carmen Lucia Contreras², Maria Renee Lopez², Chris Bernart², Juan Carlos Moir³, Kenneth Escobar⁴, Lisette Reyes⁵, Wences Arvelo¹, Kim Lindblade¹, Leonard Peruski¹, Joe P. Bryan¹ and Jennifer R. Verani⁶

Abstract

Background: Acute respiratory infection (ARI) is an important cause of mortality in children and adults. However, studies assessing risk factors for ARI-related deaths in low- and middle-income settings are limited. We describe ARI-related death and associated factors among children aged < 2 years and adults aged ≥18 years hospitalized with ARI in Guatemala.

Methods: We used respiratory illness surveillance data in Guatemala from 2007 to 2013. ARI was defined as evidence of acute infection and ≥1 sign/symptom of respiratory disease in hospitalized patients. Clinical, sociodemographic, and follow-up data were gathered. Nasopharyngeal/oropharyngeal swabs were collected from patients with ARI and tested for 6 respiratory viruses; urine was collected only from adults with ARI and tested for pneumococcal antigen. Blood cultures and chest radiographs were performed at the physician’s discretion. Radiographs were interpreted per World Health Organization guidelines to classify endpoint pneumonia (i.e. suggestive of bacterial pneumonia). Multivariable logistic regression was used to compare characteristics of patients with fatal cases, including those who died in-hospital or were discharged in a moribund state, with those of patients with non-fatal cases.

Results: Among 4109 ARI cases identified in hospitalized children < 2 years old, 174 (4%) were fatal. Median age at admission was 4 and 6 months for children with fatal and non-fatal cases, respectively. Factors associated with fatality included low weight-for-age, low family income, heart disease, and endpoint pneumonia; breastfeeding and respiratory syncytial virus (RSV) detection were negatively associated with fatality. Among 1517 ARI cases identified in hospitalized adults ≥18 years, 181 (12%) episodes were fatal. Median age at admission was 57 years for adults with fatal and non-fatal cases. Low body mass index, male sex, kidney disease, and endpoint pneumonia were significantly more common among patients with fatal versus non-fatal cases.

Conclusions: Our findings highlight some of the factors that must be addressed in order to reduce ARI-related mortality, including promotion of good nutrition, breastfeeding, management and prevention of chronic comorbidities, and poverty reduction. Although no specific pathogen increased risk for death, endpoint pneumonia was significantly associated with fatality, suggesting that the pneumococcal conjugate vaccine could contribute to future reductions in ARI-related mortality.

Keywords: Acute respiratory infection, Death, Risk factors
Background
Acute respiratory infection (ARI) is a leading cause of death in children and contributes to a substantial amount of mortality in adults worldwide. It is estimated that 11–22% of deaths among children aged <5 years and 3% of deaths among adults aged 15–49 years globally are due to ARI [1, 2]. In Central America, ARI is the fourth leading cause of death among people of all ages [2]. Efforts to reduce ARI burden should include strategies to prevent infections from occurring and to prevent death among patients who become infected.

The integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea provides a framework for evidence-based interventions and an integrated approach to ending preventable pneumonia and diarrhea deaths [3]. The plan highlights the need to use data to identify groups at greater risk for death and to develop targeted approaches. The World Health Organization (WHO) and the Child Health and Nutrition Research Initiative have also recognized the identification of key risk factors for the development of severe and fatal pneumonia as a research priority, particularly in low- and middle-income countries [4]. Such data can be used to guide policy decisions and the prioritization of prevention interventions. Although the burden of ARI-related mortality is disproportionately high in low- and middle-income settings, studies assessing risk factors associated with ARI-related deaths in these settings remain limited [5]. Many studies are restricted to specific settings or populations (e.g. specific respiratory pathogens such as influenza A H1N1 during the global pandemic or limited assessment of variables only in young children) rather than all ARI-related mortality among both children and adults [6–16].

To inform efforts to prevent deaths due to ARI, we assessed factors associated with ARI-related deaths in these settings. Studies assessing risk factors associated with ARI-related deaths in these settings remain limited [5]. Many studies are restricted to specific settings or populations (e.g. specific respiratory pathogens such as influenza A H1N1 during the global pandemic or limited assessment of variables only in young children) rather than all ARI-related mortality among both children and adults [6–16].

Methods
Setting
The Vigilancia Integrada Comunitaria (ViCo) surveillance system is a facility-based integrated surveillance system for respiratory, diarrheal, febrile and neurologic illness in Guatemala. The surveillance system, described in more detail elsewhere [17, 18], was established in 2007 by Universidad del Valle de Guatemala (UVG) in collaboration with the Guatemala Ministry of Public Health and Social Welfare and Centers for Disease Control and Prevention (CDC). ViCo has been implemented at three sites in in Guatemala: Santa Rosa Hospital (176 bed capacity including four pediatric and eight adult intensive care unit beds [ICU]) located 50 km southeast of the capital Guatemala City, Quetzaltenango Hospital (425 bed capacity including 22 pediatric and six adult ICU beds) located 120 km northwest of the capital, and the Guatemalan Institute for Social Security, a hospital in the capital Guatemala city (179 bed capacity and 10 pediatric and ICU beds; only children enrolled at this site).

Data collection
At each site, surveillance nurses reviewed registers and emergency department logs to identify patients admitted with an acute infectious disease. These patients were screened for study eligibility as ARI patients. ARI was defined as evidence of acute infection and ≥1 sign/symptom of respiratory disease. Evidence of acute infection included fever (≥38 °C), hypothermia (< 35 °C), abnormal white blood cell count (< 5 years of age: < 5500 or > 15,000; ≥5 years of age: < 3000 or > 11,000), or abnormal white blood cell differential. Signs or symptoms of respiratory disease included tachypnea, cough, sputum production, pleuritic chest pain, hemoptysis, difficulty breathing, shortness of breath, and sore throat; in addition, for children < 2 years old, signs included chest indrawing, nasal flaring, noisy breathing, and difficulty eating, drinking, or breastfeeding.

Patients meeting the ARI case definition or their parents/guardians were interviewed by surveillance nurses to gather demographic and epidemiological information. A study nurse abstracted the clinical data from the medical chart. Study nurses collected nasopharyngeal (NP) and oropharyngeal (OP) swabs, urine samples (from patients aged ≥18 years; urine antigen testing has low specificity in children due to frequent nasopharyngeal colonization [19]), and, when possible, measured peripheral oxygen saturation using a pulse oximeter with the patient off oxygen. Blood cultures and chest radiographs (CXR) were performed at the discretion of the treating physician. Digital images of CXRs were captured and reviewed by a panel of radiologists as per WHO guidelines for standardized interpretation of CXRs [20]; although the guidelines were developed for pediatric CXRs, the same criteria were applied for CXRs from patients of all ages. The images were classified as ‘end-point pneumonia,’ suggestive of bacterial etiology, when lobar consolidation and/or effusion were observed; other classifications included ‘other consolidation/infiltrate,’ no consolidation/infiltrate/effusion’ or ‘uninterpretable’ [21]. Enrolled patients were followed during their hospital stay, and data on outcomes were captured by study nurses. Patients were classified as “discharged moribund” if the chart indicated that they were terminally ill at the time of discharge. Follow-up contact was attempted three to 6 weeks after discharge to assess post-discharge sequelae or death.
NP and OP swabs were stored in viral transport media at 4°C and real-time reverse transcriptase polymerase chain reaction was used to test for adenovirus, parainfluenza virus 1/2/3, respiratory syncytial virus (RSV), influenza A and B, and human metapneumovirus at UVG following CDC protocols [22–24]. Urine specimens were tested for *Streptococcus pneumoniae* antigen using Binax NOW (Binax Inc., Scarborough, ME, USA) tests. Blood cultures were performed at on-site laboratories in each surveillance hospital using standard microbiologic methods as previously described [17].

**Ethics**

The surveillance protocol received approval from the institutional review boards of UVG (Guatemala City, Guatemala) and CDC (Atlanta, GA, USA) and the National Health Ethics Committee of the Guatemala Ministry of Public Health and Social Welfare. Verbal consent was obtained from all patients prior to eligibility screening; written informed consent was obtained from all eligible patients willing to participate. Parents or guardians provided consent for patients <18 years.

**Data management and analysis**

All data were entered into hand-held personal digital devices with pre-programmed quality checks and stored using Microsoft SQL Server 2008 (Redmond, VA, USA). ARI patients enrolled from September 2007 through December 2013 were included in the analysis. Certain variables were available only for children aged <2 years (e.g. breastfeeding, prematurity) and others only for adults ≥18 years (e.g. history of patient smoking), so children aged 2 to 17 years were not included in the analysis; 8% (n = 31) of all ARI patients with fatal cases were in this age group. Malnutrition in children aged <2 years was defined as weight-for-age Z score <−2 using WHO growth curves [25]; low body mass index (BMI) in adults was defined as <18.5 kg/m² [26]. Family monthly income was measured according to the Guatemala currency Quetzal (Q). Patients who self-discharged against medical advice, were transferred, or who had missing discharge status were excluded from the analysis. Cases in which the ARI patient died in-hospital or was discharged home in a moribund condition were classified as fatal cases. Moribund patients were included based on an analysis of follow-up data 30 days post-discharge showing that 86% (19/22) of ARI patients aged <2 years discharged in a moribund condition died post-discharge as compared to 0.6% (11/1876) of those discharged in a non-moribund condition (unpublished data). Likewise, 94% (29/31) of ARI patients aged ≥18 years discharged in moribund condition died post-discharge as compared to 3% (26/906) of those discharged in a non-moribund condition.

Characteristics of ARI patients with fatal cases were compared to those of patients with non-fatal cases, using a chi-squared test for categorical variables and a Wilcoxon-Mann-Whitney test for non-normal continuous variables. Pathogen specific case fatality ratios with 95% confidence intervals (CIs) were calculated. Multivariable logistic regression was used to assess risk factors for fatality among ARI patients. Models were developed using manual selection based on univariate effects, statistical significance (p < 0.1), and biologic plausibility (e.g. age was kept in the model a priori). Variable correlation was assessed. Interaction between age and pathogens was also tested. Models were evaluated using fit statistics (i.e. Akaike’s information criterion and Schwarz criterion), the Hosmer and Lemeshow Goodness of Fit Test, the C statistic, and an assessment of outliers. SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.

**Results**

**Children aged <2 years**

From September 2007 to December 2013, 4597 children aged <2 years old were hospitalized with ARI. After excluding 488 (11%) patients who transferred, discharged against medical advice, or had missing status at discharge, a total of 4109 ARI cases were available for analysis, of which 174 (4%) were fatal (including 145 in-hospital deaths and 29 cases in patients discharged moribund) (Fig. 1). Median age of patients with fatal and non-fatal ARI cases was four and 6 months, respectively; over half in both groups were male (Table 1). More than 96% of patients with both fatal and non-fatal cases had a NP/OP swab collected; at least one virus was detected in 53% of patients with fatal cases and 69% of patients with non-fatal cases (p < 0.0001). Blood culture was performed for 33 and 20% of patients with fatal and non-fatal cases, respectively (p = < 0.0001); very few respiratory pathogens were detected by blood culture among children (Table 1). Chest radiography was performed on 56% of enrolled ARI patients; 49/104 (47%) patients with fatal cases and 562/2197 (26%) patients with non-fatal cases had endpoint pneumonia.

On multivariable analysis, the factor most strongly associated with death was low weight-for-age Z score (adjusted odds ratio [aOR]: 7.0; 95% confidence intervals [CI]: 4.1–12.8), with 86% of patients with fatal cases having a low weight-for-age Z score compared to 40% of patients with non-fatal cases. Other factors significantly associated with death included family monthly income <Q1000 (aOR: 2.2; 95% CI: 1.4–3.6), a history of heart disease (aOR: 3.0; 95% CI: 1.2–6.8), and endpoint pneumonia (aOR: 2.5; 95% CI: 1.6–3.8). Breastfeeding in the first 2 years of life (aOR: 0.6; 95% CI: 0.4–0.9) and RSV detection (aOR: 0.5; 95% CI: 0.3–0.8) were significantly
less common among patients with fatal cases compared with those with non-fatal cases (Table 1). Although neither agent was significantly associated with fatality, influenza A (7%) and adenovirus (5%) had the highest pathogen-specific case fatality ratios (Table 3).

**Adults aged ≥18 years**

During the study period, 1577 adults ≥18 years old were hospitalized with ARI. After excluding 60 (4%) patients who transferred, self-discharged against medical advice, or had missing status, a total of 1517 ARI cases were available for analysis, of which 181 (12%) were fatal (including 144 in-hospital deaths and 37 cases in patients discharged moribund) (Fig. 2). Median age of hospitalized ARI patients was 57 years; approximately half were male (Table 2). More than 97% of patients with both fatal and non-fatal cases had a NP/OP swab collected; at least one virus was detected in 29% of patients with fatal cases and in 27% of patients with non-fatal cases. Blood culture was performed for 26 and 21% of patients with fatal and non-fatal cases, respectively ($p = 0.15$) and pathogens detected are seen in Table 2. Chest radiography was performed on 63% of enrolled ARI patients; 73/117 (62%) of patients with fatal cases and 335/833 (40%) of patients with non-fatal cases had endpoint pneumonia.

On multivariable analysis, the factor most strongly associated with death was low BMI (aOR: 3.4; 95% CI: 2.4–5.1), with 79% of patients with fatal cases having a low BMI, compared to 49% of patients with non-fatal cases. Other factors significantly associated with death included male sex (aOR: 1.6; 95% CI: 1.1–2.2), a history of kidney disease (aOR: 2.1; 95% CI: 1.2–3.4), and endpoint pneumonia (aOR: 1.8; 95% CI: 1.2–2.8) (Table 2). Although no pathogens were associated with fatality, adenovirus (16%), parainfluenza (15%), and influenza A (13%) had the highest case fatality ratios among viral pathogens. *S. pneumoniae* had a 10–21% case fatality ratio (see Table 3).

**Discussion**

We found a substantial burden of mortality among hospitalized ARI patients, with 4% of patients <2 years old and 12% of adult patients dying during hospitalization or discharged in a moribund state. Although the case fatality proportion among children was lower than that of adults, children hospitalized with ARI outnumbered adults hospitalized with ARI by almost three to one. We identified several factors associated with fatality among hospitalized ARI patients, including malnutrition, lack of breastfeeding, certain medical conditions, low socioeconomic status, and male sex, in these age groups. Although we did not find any specific pathogens to be positively associated with fatality, endpoint pneumonia, which is suggestive of bacterial pneumonia [20], was more common among patients with fatal ARI cases.

We found malnutrition to be an important risk factor for ARI-related fatality among both young children and adults. Several other studies have similarly reported on the link between malnutrition and respiratory deaths. Two systematic reviews from studies in low- and middle-income countries found that both severe
Table 1: Patient characteristics and pathogens associated with fatality in children aged < 2 years hospitalized with acute respiratory infection (ARI) in Guatemala from September 2007 through December 2013 (N = 4109)

| Variable                                                                 | Fatal (%) (n = 174) | Non-fatal (%) (n = 3935) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|--------------------------------------------------------------------------|----------------------|--------------------------|----------------__|---------------------|
| Age at admission in months, median (IQR)                                | 4 (2–9)              | 6 (2–11)                 | 1.0 (0.9–1.0)    | –                   |
| Male sex                                                                 | 105/174 (60)         | 2280/3935 (58)           | 1.1 (0.8–1.5)    | –                   |
| Family monthly income <Q1000                                            | 123/174 (71)         | 2015/3935 (51)           | 2.2 (1.7–3.2)    | 2.2 (1.4–3.6)       |
| Amerindian Indigenous                                                    | 61/174 (35)          | 1227/3935 (31)           | 1.2 (0.9–1.6)    | –                   |
| Hospital Site                                                            |                      |                          |                 |                     |
| Santa Rosa                                                               | 91/174 (52)          | 1561/3935 (40)           | Reference       | –                   |
| Quetzaltenango                                                           | 72/174 (41)          | 1484/3935 (38)           | 0.8 (0.6–1.1)    | –                   |
| Guatemala City                                                           | 11/174 (6)           | 890/3935 (23)            | 0.2 (0.1–0.4)    | –                   |
| High crowding index (> 3 persons/room)                                  | 88/174 (51)          | 1900/3935 (48)           | 1.1 (0.8–1.5)    | –                   |
| Parent completed primary school                                          | 72/173 (42)          | 2114/3919 (54)           | 0.6 (0.4–0.8)    | –                   |
| A person in the household smokes                                        | 51/171 (18)          | 797/3898 (20)            | 0.9 (0.6–1.3)    | –                   |
| Breastfed in first 2 years of life                                      | 72/172 (42)          | 2101/3924 (54)           | 0.6 (0.5–0.9)    | 0.6 (0.4–0.9)       |
| Sought care prior to hospitalization                                    | 121/173 (70)         | 2570/3879 (66)           | 1.2 (0.9–1.7)    | –                   |
| Received ≥ 1 dose of DPT/Hib, Hep B vaccine                             | 73/137 (53)          | 2231/3312 (67)           | 0.6 (0.4–0.8)    | –                   |
| Low weight-for-age Z score (<−2 SD), n (%)                              | 149/174 (86)         | 1563/3935 (40)           | 9.0 (6.0–14.2)   | 7.0 (4.1–12.8)      |
| Medical history                                                          |                      |                          |                 |                     |
| Any chronic disease                                                     | 26/170 (15)          | 219/3857 (6)             | 3.0 (1.9–4.6)    | –                   |
| Heart disease                                                           | 19/165 (12)          | 108/3859 (3)             | 4.5 (2.6–7.4)    | 3.0 (1.2–6.8)       |
| Asthma                                                                  | 2/169 (1)            | 57/3879 (1)              | 0.8 (0.1–2.6)    | –                   |
| Chronic pulmonary disease                                               | 2/166 (1)            | 24/3855 (1)              | 1.9 (0.3–6.6)    | –                   |
| Diabetes                                                                | 0/167 (0)            | 3/3870 (0.1)             | –                | –                   |
| Cancer                                                                  | 0/166 (0)            | 1/3861 (0.03)            | –                | –                   |
| Liver disease                                                           | 0/166 (0)            | 5/3852 (0.1)             | –                | –                   |
| Kidney disease                                                          | 0/166 (0)            | 7/3856 (0.2)             | –                | –                   |
| HIV                                                                     | 0/159 (0)            | 3/3809 (0.1)             | –                | –                   |
| Prematurity                                                             | 48/168 (29)          | 1049/3872 (27)           | 1.1 (0.8–1.5)    | –                   |
| Endpoint pneumonia                                                      | 49/104 (47)          | 562/2197 (26)            | 2.6 (1.7–3.9)    | 2.5 (1.6–3.8)       |
| Pathogens detected by NP/OP swab                                       |                      |                          |                 |                     |
| NP/OP swab tested                                                       | 169/169 (100)        | 3780/3781 (99)           | –                |                     |
| Any viral detection                                                     | 90/169 (53)          | 2609/3780 (69)           | 0.5 (0.4–0.7)    | –                   |
| Respiratory syncytovirus                                               | 50/169 (30)          | 1632/3780 (43)           | 0.6 (0.4–0.8)    | 0.5 (0.3–0.8)       |
| Adenovirus                                                             | 23/169 (14)          | 399/3780 (11)            | 1.3 (0.8–2.0)    | –                   |
| Parainfluenza 1/2/3                                                    | 14/169 (8)           | 445/3780 (12)            | 1.9 (1.0–3.9)    | –                   |
| Influenza A                                                            | 14/169 (8)           | 179/3780 (5)             | 1.8 (1.0–3.1)    | –                   |
| Human metapneumovirus                                                  | 9/169 (5)            | 357/3780 (9)             | 0.5 (0.3–1.0)    | –                   |
| Influenza B                                                            | 1/169 (0.6)          | 40/3780 (1)              | 0.6 (0.3–2.6)    | –                   |
| Pathogens detected by blood culture                                     |                      |                          |                 |                     |
| Blood culture performed                                                 | 57/174 (33)          | 805/3935 (20)            | –                |                     |
| Evidence of contamination                                              | 4/57 (7)             | 84/805 (10)              | 0.6 (0.2–1.6)    | –                   |
| Any growth                                                              | 13/57 (23)           | 173/805 (21)             | 1.1 (0.5–2.0)    | –                   |
| Streptococcus pneumonia                                                | 0/57 (0)             | 0/805 (0)                | –                | –                   |
| Pseudomonas aeruginosa                                                 | 0/57 (0)             | 3/805 (0.4)              | –                | –                   |
| Staphylococcus aureus                                                  | 0 (0)                | 21/805 (3)               | –                | –                   |

Abbreviations: IQR interquartile range

a0/29 patients aged < 2 months with fatal cases and 39/674 patients aged < 2 months with non-fatal cases were vaccinated, although they were not yet age-eligible to receive DPT/Hib, Hep B vaccine

bAmong those tested
malnutrition (OR range: 2.5–15) and moderate malnutrition (OR range: 1.2–36.5) significantly increased the risk of mortality among children with pneumonia and ARI [27]. However, data on the role of nutrition and ARI-related mortality in adults are more limited. In one Kenyan study, BMI was not a significant risk factor for mortality among adults with acute pneumonia [16]. However, low BMI may be a marker for serious underlying illness. One study among Navajo adults found that low BMI was associated with the risk of invasive pneumococcal disease [28]. In selected studies, obesity was also found to be a significant risk factor for death during the 2009 H1N1 influenza pandemic [8, 10].

Further research is needed to better understand how nutritional status, particularly malnutrition, affects risk of mortality among adults with ARI. Malnutrition could be associated with a poor immune response, making an individual more susceptible to infections including pneumonia, and infections can also contribute to malnutrition [29]. In Guatemala, the national nutritional survey Nacion del Salud Materna Infantil (ENSIMI) published in 2017 reported that 46.5% of children <5 years of age experience chronic malnutrition [30]. Importantly, malnutrition is a modifiable risk factor and improvements in nutritional status through interventions such as programs targeting improved diets and vitamin A and zinc supplementation can reduce the risk of developing pneumonia, as well as the risk of death among children with pneumonia. One study estimated that an intervention that prevented 40% of childhood cases of malnutrition in developing countries could lead to a 5.1–13.3% reduction in deaths from pneumonia, depending on the region [31].

Breastfeeding was protective against death in patients aged <2 years in this study, even after adjusting for malnutrition, providing evidence of the benefits of breastfeeding beyond improved nutrition. Similarly, a multicentre cohort study in low- and middle-income countries found that infants aged 6–26 weeks not breastfed had an adjusted hazard ratio of 32.7 (95% CI: 6.8–157.2) for ARI-specific mortality compared to those exclusively breastfed, although this was a community-based study in contrast to our hospital-based study [32]. A systematic review including community- and hospital-based studies from 39 low- and middle-income countries found that inadequate breastfeeding practices were significantly associated with an increased risk of ARI-related death (OR: 1.8, 95% CI: 1.2–2.0) [6]. Maternal antibodies against infectious causes of respiratory disease can help reduce the severity of illness in the breastfeeding child [33]. Promotion of exclusive breastfeeding is an important public health intervention for reducing the burden of respiratory morbidity and mortality among young children. High utilization of outpatient care among pneumonia and influenza-like illness patients have been reported in Guatemala so community-based providers should be empowered to provide appropriate public health education and interventions such as the promotion of nutrition, breastfeeding and vaccination for the control of ARI [34].

We also found poverty to be associated with fatality among young children, which may reflect a wide range of inter-related factors including baseline health status, environmental exposures, and access to medical care. A systematic review found that low socioeconomic status was associated with an increased risk of ARI-related
Table 2: Patient characteristics and pathogens associated with fatality in adults aged ≥18 years hospitalized with acute respiratory infection (ARI) in Guatemala from September 2007 through December 2013 (N = 1517)

| Variable | Fatal (n = 181) n (%) | Non-fatal (n = 1336) n (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|----------|-----------------------|---------------------------|------------------|---------------------|
| Age at admission in years, median (IQR) | 57 (39–74) | 57 (39–71) | 1.0 (1.0–1.0) | – |
| Male sex | 93/181 (51) | 570/1336 (43) | 1.4 (1.0–1.9) | 1.8 (1.2–2.7) |
| Family monthly income <Q1000 | 96/181 (53) | 834/1336 (62) | 0.7 (0.5–0.9) | – |
| Amerindian Indigenous | 78/181 (43) | 471/1336 (35) | 1.4 (1.0–1.9) | – |
| Hospital Site | | | | |
| Quetzaltenango | 110/181 (61) | 655/1336 (49) | 1.6 (1.2–2.2) | – |
| Santa Rosa | 71/181 (39) | 681/1336 (51) | Reference | – |
| High crowding index (> 3 persons/room) | 44/181 (24) | 322/1336 (24) | 1.0 (0.7–1.4) | – |
| Patient completed primary school | 60/180 (33) | 396/1334 (30) | 1.2 (0.8–1.6) | – |
| History of smoking | 20/177 (11) | 151/1331 (11) | 1.2 (0.8–1.8) | – |
| Sought care prior to hospitalization | 88/179 (49) | 542/1335 (41) | 1.4 (1.0–1.9) | – |
| Received influenza vaccine in past 6 months | 6/156 (4) | 33/1188 (3) | 1.4 (0.5–3.2) | – |
| Low body mass index (< 18.5 kg/m²) | 143/181 (79) | 661/1336 (49) | 3.8 (2.7–5.7) | 3.4 (2.1–5.7) |
| Medical history | | | | |
| Any chronic disease | 99/180 (55) | 666/1336 (50) | 1.2 (0.9–1.7) | – |
| Hypertension | 48/167 (29) | 268/1303 (21) | 1.6 (1.1–2.2) | – |
| Diabetes | 31/174 (18) | 182/1325 (14) | 1.4 (0.9–2.0) | – |
| Kidney disease | 26/174 (15) | 79/1320 (6) | 2.8 (1.7–4.4) | 2.4 (1.3–4.3) |
| Heart disease | 21/174 (12) | 86/1320 (7) | 2.0 (1.2–3.2) | – |
| Chronic pulmonary disease | 13/174 (7) | 105/1320 (8) | 0.9 (0.5–1.6) | – |
| Asthma | 9/176 (5) | 137/1327 (10) | 0.5 (0.2–0.9) | – |
| Liver disease | 9/174 (5) | 24/1321 (2) | 2.9 (1.3–6.2) | – |
| HIV | 8/166 (5) | 22/1296 (2) | 2.9 (1.2–6.4) | – |
| Cancer | 3/175 (2) | 20/1324 (2) | 1.1 (0.3–3.4) | – |
| End-point pneumonia | 73/117 (62) | 335/833 (40) | 2.5 (1.7–3.7) | 1.9 (1.3–2.9) |
| Pathogens detected by NP/OP swab | | | | |
| NP/OP swab tested | 176/177 (99) | 1292/1292 (100) | – | – |
| Any viral detectiona | 51/176 (29) | 343/1292 (27) | 1.1 (0.8–1.6) | – |
| Influenza Aa | 18/176 (10) | 116/1292 (9) | 1.2 (0.7–1.9) | – |
| Adenovirusa | 12/176 (7) | 62/1292 (5) | 1.5 (0.7–2.7) | – |
| Respiratory syncytial virusa | 11/176 (6) | 87/1292 (7) | 0.9 (0.5–1.7) | – |
| Parainfluenza 1/2/39 | 11/176 (6) | 62/1292 (5) | 1.3 (0.7–2.5) | – |
| Human metapneumovirusa | 3/176 (2) | 25/1292 (2) | 0.9 (0.2–2.5) | – |
| Influenza B9 | 1/176 (0.6) | 22/1292 (2) | 0.3 (0.02–1.6) | – |
| Pathogens detected by blood culture | | | | |
| Blood culture performed | 47/181 (26) | 284/1336 (21) | – | – |
| Evidence of contaminationa | 1/47 (2) | 8/284 (3) | 0.8 (0.04–4.2) | – |
| Any growthsa | 13/47 (28) | 38/284 (13) | 2.5 (1.2–5.0) | – |
| Streptococcus pneumoniae9 | 3/47 (6) | 11/284 (4) | 1.7 (0.4–5.7) | – |
| Staphylococcus aureusa9 | 2/47 (4) | 3/284 (1) | 4.2 (0.5–25.8) | – |
| Pseudomonas aeruginosa9 | 0/47 (0) | 1/284 (0.4) | – | – |
| Pathogens detected by urine antigen testing | | | | |
| Urine antigen testing conducted | 134/163 (82) | 1076/1188 (91) | – | – |
death among children aged less than 5 years (OR: 1.6, 95% CI: 1.3–2.0) [6]. Although poverty is not an easily modifiable risk factor, poverty reduction efforts could reduce the burden of ARI-related deaths as well as deaths from other diseases closely linked to socioeconomic status.

Comorbidities have been shown to be risk factors for ARI death among both children and adults. Among children, the most commonly reported comorbidity linked to ARI death is heart disease [6, 35–37], as was found in our study among children < 2 years. Among adults, most studies assessing risk factors for ARI-related death have focused on patients hospitalized with influenza. These studies have identified a range of comorbidities associated with fatality, although diabetes is commonly reported to have the strongest association [7–12]. Diabetes was not a risk factor for death in our study. We found kidney disease to be the only comorbidity associated with fatality, similar to another finding reported in a study on influenza-related fatalities [11].

Endpoint pneumonia was more common among patients with fatal ARI cases in both children aged < 2 years and adults. Endpoint pneumonia is considered a proxy for bacterial pneumonia in children [20] and has been used as an outcome for clinical trials and observational studies of household air pollution [38] and of vaccines against Haemophilus influenzae type b and S. pneumoniae [39]. Although experience with standardized CXR interpretation in adults is more limited, data from this same surveillance platform in Guatemala suggest that it can be used to identify adults more likely to have pneumococcal pneumonia [40]. We did not find S. pneumoniae isolated by blood culture or detected through urine antigen testing to be associated with death; however the number of positive results were limited, and blood culture is insensitive for detecting S. pneumoniae [41]. Nonetheless, the importance of endpoint pneumonia suggests that S. pneumoniae may be an important cause of ARI-related death in Guatemala. The 13-valent pneumococcal conjugate vaccine was introduced in Guatemala in 2011. It has been found to be protective against endpoint pneumonia, so although coverage remained fairly low during the study period, increased uptake of the vaccine could lead to reductions in pneumonia burden and potentially ARI deaths [42].

RSV is a leading cause of respiratory illness and death among children globally [43, 44], and was the most commonly detected virus among both fatal and nonfatal ARI cases in children < 2 years old in this study. Despite the well-recognized burden of RSV, we found it to be significantly more common among ARI patients discharged alive (43%) than among patients with fatal ARI cases

### Table 2

| Variable                                      | Fatal (n = 181) n (%) | Non-fatal (n = 1336) n (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-----------------------------------------------|-----------------------|---------------------------|-------------------|----------------------|
| Streptococcus pneumoniae<sup>a</sup>          | 16/134 (12)           | 147/1076 (14)             | 0.9 (0.5–1.4)     | –                    |
| Viral co-infection with S. pneumoniae<sup>a,b</sup> | 5/178 (3)             | 50/1322 (4)               | 1.4 (0.6–4.0)     | –                    |

<sup>a</sup>Among those tested  
<sup>b</sup>Results from blood culture and urine antigen testing combined

### Table 3

| Pathogen                   | CFR in children < 2 years (%) | CFR in adults ≥18 (%) |
|----------------------------|-------------------------------|-----------------------|
| Influenza A<sup>a</sup>    | 14/193 (7)                    | 18/134 (13)           |
| Adenovirus<sup>a</sup>     | 23/422 (5)                    | 12/74 (16)            |
| Parainfluenza 1/2/3<sup>a</sup> | 14/459 (3)                  | 11/73 (15)            |
| Respiratory syncytial virus<sup>a</sup> | 50/1682 (3)                | 11/98 (11)            |
| Human metapneumovirus<sup>a</sup> | 9/366 (2)                   | 3/28 (11)             |
| Influenza B<sup>b</sup>    | 1/41 (2)                      | 1/23 (4)              |
| Staphylococcus aureus<sup>b</sup> | 0/21 (0)                    | 2/5 (40)              |
| Pseudomonas aeruginosa<sup>b</sup> | 0/3 (0)                     | 0/1 (0)               |
| Streptococcus pneumoniae<sup>b</sup> | –                           | 3/14 (21)            |
| Streptococcus pneumoniae<sup>c</sup> | –                           | 16/163 (10)          |
| Viral co-infection with S. pneumoniae<sup>d</sup> | –                           | 5/55 (9)             |

<sup>a</sup>Tested by NP/OP swab  
<sup>b</sup>Tested by blood culture  
<sup>c</sup>Tested by urine antigen testing  
<sup>d</sup>Includes blood culture and urine antigen tested for adults ≥18 years
(30%). This finding may be a reflection of the comparison group used for analysis and the insensitivity of available tests for bacterial causes of respiratory illness in children [45]. For example, if S. pneumoniae were relatively more common among RSV-negative patients than RSV-positive patients, and S. pneumoniae were more strongly associated with death than RSV, then RSV detection may appear to be protective against death; however the insensitivity of tests for S. pneumoniae limits our ability to test this hypothesis. Many ARI-related deaths among children occur at home without seeking medical care [46]. If children with RSV infection were less likely to receive care at the hospital (for example, due to absence of fever among many RSV case-patients) compared to children with other respiratory etiologies, then RSV-related deaths might be under-represented in our study. Overall ARI pathogen etiology results are discussed in more detail in Verani et al. and found to be similar to more recent respiratory disease surveillance studies [17, 47].

This study has limitations that should be acknowledged. Data on at-home deaths after hospital discharge were not systematically collected among all patients and this could have resulted in misclassification; some discharged alive may have died at home as a result of their illness and some discharged in a moribund state may have survived. Some characteristics that have been identified as risk factors for death among pneumonia patients in other studies were not adequately measured in this study to assess their possible role, including factors such as low birthweight, other infectious diseases such as malaria or measles, environmental factors, and poor water, sanitation and hygiene access/practices. Pathogen detection was limited by lack of specimens from the site of infection (e.g. inside the lung), available diagnostic tools, lack of blood culture sensitivity, and inability to use urine antigen testing in children because nasopharyngeal colonization is common and may lead to false positive results [19]. Improved rapid point of care diagnostic tests for viral and bacterial respiratory tract infections are needed to better understand the role of each pathogen and improve management outcomes [48]. It is also worth noting that the ARI case definition could have affected results although it has been found in other studies to have high sensitivity and capture more than 67% of RSV-associated hospitalizations [49]. Other variables, including selected vaccinations, end-point pneumonia, and urine antigen testing had significant missing data, which could have biased results. Lastly, our comparison group was patients hospitalized with ARI, rather than healthy controls, so we were not describing factors associated with the development of ARI or population-based incidence of ARI mortality, but rather those associated with death among ARI patients.

Conclusions
Efforts to control respiratory disease and end preventable deaths should be based on evidence, particularly in low- and middle-income countries where data are often more limited despite a higher burden of morbidity and mortality. Our results identify important risk factors for ARI-related death and highlight the importance of strategies to promote improved nutrition and breastfeeding, as well as the prevention and management of chronic illnesses such as kidney and heart disease. Increasing coverage with the pneumococcal conjugate vaccine is expected to lead to reductions in ARI-related mortality in this population. Our findings underscore the need to use a wider approach for prevention and control of ARI fatality, including consideration of the factors we highlight above and as reflected in and the United Nations Sustainable Development Goals [50].

Abbreviations
ARI: Acute respiratory infection; BMI: Body mass index; CI: Confidence interval; CXR: Chest radiograph; ICU: Intensive care unit; NP: Nasopharyngeal; OP: Oropharyngeal; RSV: Respiratory syncytial virus; UVG: Universidad del Valle de Guatemala; VICO: Vigilancia Integrada Comunitaria; WHO: World Health Organization

Acknowledgements
We thank all patients who consented to enrollment in the study.

Funding
Centers for Disease Control and Prevention provided funding for the design of the study, data collection, analysis and interpretation, and writing of the manuscript. However, the findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Availability of data and materials
The dataset analyzed during the current study is available from the corresponding author on reasonable request.

Authors’ contributions
JM, CLC, MRL, CB, JCM, KE, and LR conducted data collection. ST and JV analyzed and interpreted the data and wrote the initial manuscript draft. JM, CLC, WA, KL, LP and JB critically reviewed the data analysis and written manuscript and provided feedback. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The surveillance protocol received approval from the institutional review boards of UVG (Guatemala City, Guatemala) and CDC (Atlanta, GA, USA) and the National Health Ethics Committee of the Guatemala Ministry of Public Health and Social Welfare. Verbal consent was obtained from all patients prior to eligibility screening; written informed consent from all eligible patients willing to participate- Parents/guardians provided consent for patients < 18 years.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details

1Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, USA. 2Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala. 3Quetzaltenango Health Area, Ministry of Public Health and Social Welfare, Quetzaltenango, Guatemala. 4Western Regional Hospital San Juan de Dios, Ministry of Public Health and Social Welfare, Quetzaltenango, Guatemala. 5Santa Rosa Health Area, Ministry of Public Health and Social Welfare, Cuiapa, Guatemala. 6Centers for Disease Control and Prevention, Nairobi, Kenya.

Received: 13 June 2018 Accepted: 15 April 2019 Published online: 03 May 2019

References

1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25–32.
2. Lozano R. IHME: global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):123–59.
3. WHO/UNICEF. Ending preventable child deaths from pneumonia and diarrhoea by 2025: The integrated Global Action Plan for Pneumonia and Diarrhoea. WHO: Geneva; 2013. https://apps.who.int/iris/bitstream/handle/10665/87920/9789241505239_eng.pdf. Accessed 26 Apr 2019.
4. Rудан I, El Arifeen S, Bhutta ZA, Black RE, Brooks A, Chan KY, Chopra M, Dude T, Marsh D, Pio A, et al. Setting research priorities to reduce global mortality from childhood pneumonia by 2015. PLoS Med. 2011;8(9):e1001099.
5. Rудан I, O’Brien KL, Nair H, Liu L, Theodorou E, Qazi S, Lukic I, Fischer Walker CL, Black RE, Campbell H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3(1):10041.
6. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of age in low and middle-income countries: a systematic review and meta-analysis of observational studies. PLoS One. 2015;10(1):e016380.
7. Chowell G, Echevarria-Zuno S, Viboud C, Simonsen L, Miller MA, Fernandez-Torres MA, Bencic MA, Ranieri TM, et al. Risk factors for death from pandemic (H1N1) 2009, southern Brazil. Emerg Infect Dis. 2011;17(8):1467–71.
8. Balaganesakumar SR, Murhekar MV, Swamy KK, Kumar MR, Mancham P, Pandian P. Risk factors associated with death among children infected with a (H1N1) 2009 patients, Tamil Nadu, India, 2010. J Postgrad Med. 2013;59(1):1–9.
9. Cui W, Zhao H, Lu X, Wen Y, Zhou Y, Deng B, Wang Y, Wang W, Kang J, Liu P. Factors associated with death in hospitalized pneumonia patients with 2009 H1N1 influenza in Shenyang, China. BMC Infect Dis. 2010;10:145.
10. Yokota RT, Skalinski LM, Igansi CN, de Souza LR, Iser BP, Reis PO, Barros EN, Macario EM, Bercini MA, Ranieri TM, et al. Risk factors for death from pandemic (H1N1) 2009, southern Brazil. Emerg Infect Dis. 2010;17(8):1467–71.
11. Garate I, Gonzalez-Bonilla C, Borja-Aburto VH. Epidemiological characteristics and underlying risk factors for mortality during the autumn 2009 pandemic wave in Mexico. PLoS One. 2012;7(7):e41069.
12. Victora CG, Kirkwood BR, Ashworth A, Black RE, Rogers S, Sazawal S, MacArthur LCW, Victora C, Black RE, et al. Maternal and child undernutrition and overweight in low-income countries: current status, problems, and research priorities: A multicentre cohort study. Bull World Health Organ. 2005;83(6):418–26.
13. Tondella ML, Talkingon DF, Holloway BP, Dowell SF, Cowley K, Soriano-Gabarro M, Elkind MS, Fields BS. Development and evaluation of real-time PCR-based fluorescence assays for detection of chlamydiae pneumoniae. J Clin Microbiol. 2002;40(2):575–83.
14. Zhang M, Holloway BP, Thacker W, Schwartz SB, Talkingon DF. Development of TaqMan probe-based PCR with customized internal controls for detecting Mycoplasma pneumoniae and Mycoplasma fermentans. Chicago: 99th General Meeting of the American Society for Microbiology; 1999.
15. Chhagan M, Haffejee S, Variava E, et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009–2013. J Clin Virol. 2015;68:14–20.
16. Verani JR, McCracken J, Arvelo W, Estevez A, Lopez MR, Reyes L, Moir JC, Bernat C, Moscoso F, Gray J, et al. Surveillance for hospitalized acute respiratory infection in Guatemala. PLoS One. 2013;8(12):e83600.
17. Fischer Langley G, McCracken J, Arvelo W, Estevez A, Villarruel G, Prill M, Ivane M, Gray J, Moscoso F, Reyes L, et al. The epidemiology and clinical characteristics of young children hospitalized with respiratory syncytial virus infections in Guatemala (2007-2010). Pediatr Infect Dis J. 2013;32(6):629–35.
18. Klugman KP, Madhi SA, Albritch WC. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis. 2008;47(Suppl 3):S202–6.
19. Cherenian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, Greenberg D, Lagos R, Lucero M, Madhi SA, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ. 2005;83(5):333–39.
20. WHO. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Geneva: WHO; 2001. https://apps.who.int/iris/bitstream/handle/10665/66956/WHO_V_and_B_01.35.pdf. Accessed 26 Apr 2019.
21. WHO. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Geneva: WHO; 2001. https://apps.who.int/iris/bitstream/handle/10665/66956/WHO_V_and_B_01.35.pdf. Accessed 26 Apr 2019.
22. Lindblade KA, Arvelo W, Gray J, Estevez A, Frenkel G, Reyes L, Moscoso F, Moir JC, Fry AM, Olsen SJ. A comparison of the epidemiology and clinical presentation of seasonal influenza a and 2009 pandemic influenza (H1N1) 2009 among patients in Guatemala. PLoS One. 2015;10(12):e15526.
23. Global Database on Child Growth and Malnutrition [https://www.who.int/nutgrowthdb/about/introduction/en/index5.html]. Accessed 26 Apr 2019.
24. About BMI for Adults [https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/] . Accessed 26 Apr 2019.
25. Chisti MI, Treburegge M, La Vincente S, Graham SM, Duke T. Pneumonia in severely malnourished children in developing countries - mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Tropical Med Int Health. 2009;14(10):1773–89.
26. Watt JP, O’Brien KL, Bennin AL, McCoy Si, Donaldson CM, Reid R, Schuchat A, Zell ER, Hochman M, Santoshman M, et al. Risk factors for invasive pneumococcal disease among Navajo adults. Am J Epidemiol. 2007;166(9):1080–7.
27. Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008;46(10):1582–3.
28. Ministério de Saúde Pública y Asistencia Social. Encuesta Nacional de Salud Materno Infantil 2014–2015: Informe Final. Guatemala: MSPAS; 2017. https://www.ine.gob.gt/images/2017/encuestas/ensmi2014_2015.pdf. Accessed 26 Apr 2019.
29. Victora CG, Kirkwood BR, Ashworth A, Black RE, Rogers S, Sazawal S, Campbell H, Gove S. Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition. Am J Clin Nutr. 2008;87(3):309–20.
30. Bahl R, Frost C, Kirkwood BR, Edmond K, Martines J, Bhanderi N, Arthur P. Infant feeding patterns and risks of death and hospitalization in the first half of infancy: multicentre cohort study. Bull World Health Organ. 2003;81(6):418–26.
31. Chirico G, Marzollo R, Cortinovis S, Fonte C, Gasparoni A. Antinfective properties of human milk. J Nutr. 2008;138(9):1805–6.
32. Lindblade KA, Johnson AJ, Arvelo W, Zhang X, Armstrong KT, Hiit, Reyes L, Fry AM, Padilla N. Low usage of government healthcare facilities for acute respiratory infections in Guatemala: implications for influenza surveillance. BMC Public Health. 2011;11:11885.
33. Ramachandran P, Nenduchelam K, Venegatens A, Suresh S. Risk factors for mortality in community acquired pneumonia among children aged 1-59 months admitted in a referral hospital. Indian Pediatr. 2012;49(11):889–95.
34. Suresh S, Sanugadha S, Raghuangchanasat S, Chantarjanasat T, Hotrakitya S. Risk factors associated with morbidity and mortality of pneumonia in Thai children under 5 years. Southeast Asian J Trop Med Public Health. 1994;25(1):60–6.
35. Deivanayagam N, Nenduchelam K, Ramasamy S, Sudhadhirakann, Ratnam SR. Risk factors for fatal pneumonia: a case control study. Indian Pediatr. 1992;29(12):1529–32.
38. Smith KR, McCracken JP, Weber MW, Hubbard A, Jenny A, Thompson LM, Balas J, Diaz A, Arana B, Bruce N. Effect of reduction in household air pollution on childhood pneumonia in Guatemala (RESPIRE): a randomised controlled trial. Lancet. 2011;378(9804):1717–26.

39. World Health Organization. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination. Geneva: WHO; 2012. https://apps.who.int/iris/bitstream/handle/10665/75835/WHO_IVB_12.08_eng.pdf. Accessed 26 Apr 2019.

40. Wortham JM, Gray J, Verani J, Contreras CL, Bernart C, Moscoso F, Moir JC, Reyes Marroquin EL, Castellan R, Arvelo W, et al. Using standardized interpretation of chest radiographs to identify adults with bacterial pneumonia—Guatemala, 2007-2012. PLoS One. 2015;10(7):e0133257.

41. Blaschke AJ. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis. 2011;52(Suppl 4):S331–7.

42. Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, Reinent RR, Schmitt H-J, Trucchi V, Vreauten T, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PloS One. 2017;12(5):e0177985.

43. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.

44. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Sazliagi PG, Griffin MR, Williams AJ, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–8.

45. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balseills A, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58.

46. Kallander K, Hildenwall H, Waiswa P, Galliwango E, Peterson S, Pariyo G. Delayed care seeking for fatal pneumonia in children aged under five years in Uganda: a case-series study. Bull World Health Organ. 2008;86(5):328–32.

47. Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, Brooks WA, Deloria Knoll M, Hammitt Ll, Howie SRC, et al. Is Higher Viral Load in the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH Study. Clin Infect Dis. 2017;64(suppl_3):S337–46.

48. Zuma A, Al-Tawfiq JA, Enne VI, Kidd M, Drosten C, Breuer J, Muller MA, Hui D, Maeufer M, Bates M, et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections--needs, advances, and future prospects. Lancet Infect Dis. 2014;14(11):1123–35.

49. Hasan R, Rhodes J, Thamthiwat S, Olsen SJ, Prapasri P, Naorat S, Chittaganpitch M, Henchachon S, Dejsirilert S, Srisaengchai P, et al. Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural Thailand. Pediatr Infect Dis J. 2014;33(2):e45–52.

50. United Nations Sustainable Development Goals, 2018 [https://sustainabledevelopment.un.org/?menu=1300] Accessed 26 Apr 2019.